Back

Effects of finerenone in patients with hypertensive nephropathy

30 August 2026 (13:45 - 14:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition Clinical ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Hiddo Heerspink

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension
Associate Professor L. Laffin (Cleveland, US)
Slides Video
Presentation thumbnail
Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies
Doctor J. Wilson (London, GB)
Slides Video
Presentation thumbnail
Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
Professor C. Lam (Singapore, SG)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 13:45 CET
You may be interested in
thumbnail
Congress Presentation
Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials
19 May 2025
thumbnail
Congress Presentation
Welcome and introductions​
30 August 2025
thumbnail
Congress Presentation
Advances in heart failure in 2025: where finerenone fits​
30 August 2025
thumbnail
Congress Session
Optimising cardiovascular risk prediction and management in patients with renal disease
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources